Aclaris Therapeutics’ A-101 45% Topical Solution Meets Primary and All Secondary Efficacy Endpoints in Second Successful Pivotal Phase 3 Clinical Trial for the Treatment of Common Warts (THWART-1)
Go back to Aclaris Therapeutics’ A-101 45% Topical Solution Meets Primary and All Secondary Efficacy Endpoints in Second Successful Pivotal Phase 3 Clinical Trial for the Treatment of Common Warts (THWART-1)| (NASDAQ: ACRS) | Delayed: 5.57 +0.07 (1.27%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $5.50 | 52 Week High | $33.88 | |||
| Open | $5.55 | 52 Week Low | $14.12 | |||
| Day High | $5.62 | P/E | N/A | |||
| Day Low | $5.40 | EPS | $0.00 | |||
| Volume | 1,521,431 | |||||
